Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Japan

GSK Files Seretide For COPD

November 2006 | Company Finance Alert

UK drug major GlaxoSmithKline (GSK) has filed its salmeterol + fluticasone propionate combination drug for Chronic Obstructive Pulmonary Disorder (COPD) in Japan. The inhalable product is more widely branded as the leading asthma treatment Advair/Seretide, and the new indication is expected to boost sales in Japan, at a time when the niche market for COPD therapies is expanding globally. The drug was filed for its core indication of adult and paediatric bronchial asthma in

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.

Related Insight Articles
Multinationals Eye Japan's Cancer Market

Companies / Japan According to industry experts, prospects for a significant expansion of Japan's US$3.2bn cancer market are set to improve significantly. New product launches by foreign-owned companies, and a health...
August 2006
Wyeth To File New Drugs In Japan

Companies / Japan US pharmaceuticals and healthcare major Wyeth is to launch more drugs in Japan this year, with regulatory filings expected for six new products. Sales efforts on the company's locally leading product,...
July 2006
Novartis Files Xolair In Japan

Companies / Japan Swiss drug major Novartis has filed its Xolair asthma treatment in Japan. If approved, the monoclonal antibody will be Japan's first-in-class therapy for severe forms of the respiratory disorder. Xolair...
July 2006
Novartis Launches Femara In Japan

Companies / Japan Swiss drugmaker Novartis and co-marketing partner Chugai have launched the aromatase inhibitor Femara (letrozole), indicated for post menopausal breast cancers, on the Japanese market. The drug's market...
May 2006
Foreign Firms Launch New Products

Companies / Japan Meanwhile, a sub-committee of the health ministry has recommended approval for US-based Schering-Plough's brain tumour drug Temodar and fellow US firm Baxter's Feiba for haemophilia. The agency also...
May 2006


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2009 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS